Tenderwize
Zurück zur Suche

Open-House-Biologika-Rabattverträge 2025-15

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 340 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of Trastuzumab (subcutaneous injection) under a discount contract with German statutory health insurance funds.
  • Conclusion of a framework-type agreement without volume commitment; no exclusivity for any contractor.
Vollständige Zusammenfassung anzeigen

Open-House procedure by German health insurance funds (led by Techniker Krankenkasse) for discount contracts on Trastuzumab (subcutaneous injection). The procedure is open to all eligible pharmaceutical entrepreneurs throughout the contract term (max. 24 months, 01.08.2025 – 31.07.2027). No estimated contract value is provided; the procedure is not a public procurement subject to EU procurement law but a voluntary publication. Participation is possible at any time during the contract term, with specific deadlines for inclusion in the monthly pharmacy software update.

Risiken

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the specific drug.
  • Must have a valid marketing authorization for Trastuzumab (subcutaneous injection) in Germany.

Eligibility

  • Must provide a self-declaration confirming eligibility and reliability.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-15

Single lot covering discount contracts for Trastuzumab (subcutaneous injection). All eligible pharmaceutical entrepreneurs can conclude a contract under uniform conditions; no exclusivity is granted. The contract ends at the latest on 31.07.2027, or earlier upon patent expiry/market exclusivity loss.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jul 2025 - Jul 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Frist

Deadline Jul 30, 2027

Vergabedetails

Veröffentlichungsdatum
19 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
323734-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3